Engineering Next-Generation CAR-T Cells for Better Toxicity Management - Archive ouverte HAL Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2020

Engineering Next-Generation CAR-T Cells for Better Toxicity Management


Immunoadoptive therapy with genetically modified T lymphocytes expressing chimeric antigen receptors (CARs) has revolutionized the treatment of patients with hematologic cancers. Although clinical outcomes in B-cell malignancies are impressive, researchers are seeking to enhance the activity, persistence, and also safety of CAR-T cell therapy-notably with a view to mitigating potentially serious or even life-threatening adverse events like on-target/off-tumor toxicity and (in particular) cytokine release syndrome. A variety of safety strategies have been developed by replacing or adding various components (such as OFF- and ON-switch CARs) or by combining multi-antigen-targeting OR-, AND- and NOT-gate CAR-T cells. This research has laid the foundations for a whole new generation of therapeutic CAR-T cells. Here, we review the most promising CAR-T cell safety strategies and the corresponding preclinical and clinical studies.
Fichier principal
Vignette du fichier
ijms-21-08620.pdf (3.7 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03295366 , version 1 (10-09-2021)



Alain E. Andrea, Andrada Chiron, Stephanie Bessoles, Salima Hacein-Bey-Abina. Engineering Next-Generation CAR-T Cells for Better Toxicity Management. International Journal of Molecular Sciences, 2020, 21 (22), ⟨10.3390/ijms21228620⟩. ⟨hal-03295366⟩
29 View
32 Download



Gmail Facebook Twitter LinkedIn More